NCT01711463View on ClinicalTrials.gov

Relovair PD PK in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 5, 2012

Primary Completion Date

June 4, 2013

Study Completion Date

June 4, 2013

Conditions
Asthma
Interventions
DRUG

Fluticasone Furoate/Vilanterol

50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.

DRUG

Placebo

Placebo inhaled once daily for 7 days in each treatment period.

Trial Locations (1)

100032

GSK Investigational Site, Beijing

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01711463 - Relovair PD PK in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter